CDK4 and melanoma: The use of both MEK and CDK4/6 inhibitors may suppress activated MAP kinase pathway and cell cycle checkpoint dysfunction in NRAS mutant melanoma, increasing antitumoral efficacy [72], by upregulating activity of the RTK-RAS-RAF and RTK-PI3K-AKT signaling cascade.